The DOI matches its Crossref record.
Effects of NIDDM on Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B Metabolism: Studies Before and After Sulfonylurea Therapy
Abstract
To evaluate mechanisms of diabetes-induced changes in very-low-density lipoprotein (VLDL), VLDL triglyceride (TG) and VLDL apolipoprotein B (apoB) metabolism were studied in 12 obese Pima Indian control subjects and in 15 Pima Indian obese non-insulin-dependent diabetics. Eleven of the diabetics were restudied after reduction of hyperglycemia with oral sulfonylurea therapy. In addition, adipose, muscle, and postheparin lipoprotein lipase and postheparin hepatic lipase activities were measured in all subjects. Obese diabetics as compared with obese controls showed a trend toward increased production of VLDL TG (46 ± 4 vs. 35 ± 6 g/day, P = .10) but not of VLDL apoB (1595 ± 106 vs. 1597 ± 164 mg/day, NS); production of VLDL TG declined to control levels (33 ± 4 g/day, P < .05) during therapy, whereas there was no change in production of VLDL apoB. Diabetics had a clearance defect for VLDL, indicated by significantly lower fractional catabolic rates for both VLDL TG (10.6 ± .9 vs. 13.1 ± .9 pools/ day, P < .05) and VLDL apoB (5.6 ± .4 vs. 7.5 ± 0.7, P < .05) as compared with controls; fractional catabolic rates increased after therapy (to 13.3 ± 1.5, P < .05, and 6.7 ± .4, P < .05, respectively). In the diabetics, this decrease in clearance was accompanied by a lower adipose lipoprotein lipase (.30 ± .09 vs. .92 ± .25 μmol · g−1 · h−1 P < .01), which increased during therapy (to .61 ± .17, P < .05). Hepatic lipase also decreased significantly after therapy (27.4 ± 3.6 to 26.4 ± 3.2, P < .01). Composition of VLDL in diabetics was also abnormal, indicated by a higher TG/apoB ratio (14.7 ± .6 vs. 11.7 ± .8, P < .01); this ratio fell during therapy (to 12.5 ± .8, P < .05). The data indicate there are multiple abnormalities in structure and metabolism of VLDL in non-insulin-dependent diabetics. Control of hyperglycemia with sulfonylureas has the capability of reversing some of these abnormalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Self-citationLipoprotein metabolism in diabetes mellitus.
Howard, B. V. (1987) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38659-4 · Cited by 636
Self-citationOates, J. A., Wood, A. J. J., & Gerich, J. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911023211805 · Cited by 480
Diraison, F., Moulin, P., & Beylot, M. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70061-7 · Cited by 435
In vivo regulation of lipolysis in humans.
Coppack, S. W., Jensen, M. D., & Miles, J. M. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41207-6 · Cited by 407
Metadata
- Authors
- Taskinen, M.-R., Beltz, W. F., Harper, I., Fields, R. M., Schonfeld, G., Grundy, S. M., & Howard, B. V.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1986-11-01
- Volume
- 35
- Issue
- 11
- Pages
- 1268-1277
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2044614810
- Cited by
- 160
- References
- 0
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of NIDDM on Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B Metabolism: Studies Before and After Sulfonylurea Therapy. https://app.cochat.ai/papers/10.2337/diab.35.11.1268
- The paper
- Taskinen, M.-R., Beltz, W. F., Harper, I., Fields, R. M., Schonfeld, G., Grundy, S. M., & Howard, B. V. (1986). Effects of NIDDM on Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B Metabolism: Studies Before and After Sulfonylurea Therapy. Diabetes. https://doi.org/10.2337/diab.35.11.1268
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.